COMM - PRISM Mid-Day Movers: Psychedelic Surge and Strategic Sales Boost Indices

2025-08-04 14:31:22 ET

Psyence BioMed Skyrockets 74% on Expanded Trial Access and Strategic Momentum
Psyence BioMed ( PBM ) soared 74.15% to lead the PRISM Emerging Psychedelics Index after announcing multiple clinical, regulatory, and operational advances . The company received Human Ethics Review Board approval to amend its clinical trial protocol by removing the terminal cancer requirement, dramatically expanding patient access and accelerating enrollment. Simultaneously, Psyence initiated three clinical trial sites and strengthened its manufacturing partnership with PsyLabs, achieving GMP-aligned Ibogaine production. With a cash position of $11.4 million and renewed Nasdaq compliance, investors embraced the companys long-term vision to become a global leader in nature-derived psychedelic therapies.

CommScope Jumps 82% on $10.5B Sale of CCS Business to Amphenol
CommScope Holding Company, Inc. ( COMM ) surged 82.61%, topping the PRISM Emerging Communications & Media Index , after entering into a definitive agreement to sell its Connectivity and Cable Solutions segment to Amphenol Corporation for $10.5 billion in cash . The company expects approximately $10 billion in net proceeds after taxes and expenses, which will be used to fully repay debt, redeem all preferred equity, and return excess cash to shareholders through a dividend post-closing. The deal, pending shareholder and regulatory approval, allows CommScope to sharpen its focus on next-gen connectivity platforms through its ANS and RUCKUS businesses.

Other PRISM Mid-Day Movers:
? GreenPower Motor Company ( GP ) up 44.44%
? BioXcel Therapeutics, Inc. ( BTAI ) up 25.91%
? Equillium, Inc. ( EQ ) down 22.13%

The post PRISM Mid-Day Movers: Psychedelic Surge and Strategic Sales Boost Indices appeared first on PRISM MarketView .

COMTEX_467790186/2927/2025-08-04T13:31:22